• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 137

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber;...

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its...

Looking Forward to Horizons Northwest, This September in Portland

Looking Forward to Horizons Northwest, This September in Portland

COMPASS Pathways to participate in three upcoming investor events

Optimi Health Provides Progress Report On Year Of Commercialization

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN...

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of...

1...136137138...291Page 137 of 291

EDITOR PICKS

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©